← back to search

Han Chong Toh

National Cancer Centre Singapore · SG
Area of research
Oncology · Hepatology
Research interest
Research interests include Hepatocellular Carcinoma Treatment and Prognosis, Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, and Colorectal Cancer Treatments and Studies.
h-index
52
citations
11,271
works
236
NIH funding
primary concept
Medicine
email

Recent publications

Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial
˜The œLancet. Gastroenterology & hepatology 2025cited by 23position: lastdoi
Serotonin receptor 5-HT<sub>2A</sub> as a potential target for HCC immunotherapy
Journal for ImmunoTherapy of Cancer 2025cited by 10position: middledoi
44d_RNAseq_data from A Pro-Regenerative Environment Triggers Premalignant to Malignant Transformation of Senescent Hepatocytes
2025cited by 0position: contributordoi
Supporting Figures from A Pro-Regenerative Environment Triggers Premalignant to Malignant Transformation of Senescent Hepatocytes
2025cited by 0position: contributordoi
Primers from A Pro-Regenerative Environment Triggers Premalignant to Malignant Transformation of Senescent Hepatocytes
2025cited by 0position: contributordoi
A multimodal atlas of hepatocellular carcinoma reveals convergent evolutionary paths and ‘bad apple’ effect on clinical trajectory
Journal of Hepatology 2024cited by 18position: middledoi
Single-cell RNA sequencing reveals anti-tumor potency of CD56+ NK cells and CD8+ T cells in humanized mice via PD-1 and TIGIT co-targeting
Molecular Therapy 2024cited by 18position: middledoi
Gemcitabine, carboplatin, and Epstein–Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial
Annals of Oncology 2024cited by 14position: firstdoi
A Pro-Regenerative Environment Triggers Premalignant to Malignant Transformation of Senescent Hepatocytes.
2023cited by 10position: contributordoi
Supporting Figures from A Pro-Regenerative Environment Triggers Premalignant to Malignant Transformation of Senescent Hepatocytes
2023cited by 1position: contributordoi
Data from A Pro-Regenerative Environment Triggers Premalignant to Malignant Transformation of Senescent Hepatocytes
2023cited by 0position: contributordoi
44d_RNAseq_data from A Pro-Regenerative Environment Triggers Premalignant to Malignant Transformation of Senescent Hepatocytes
2023cited by 0position: contributordoi
Supporting Figures from A Pro-Regenerative Environment Triggers Premalignant to Malignant Transformation of Senescent Hepatocytes
2023cited by 0position: contributordoi
Primers from A Pro-Regenerative Environment Triggers Premalignant to Malignant Transformation of Senescent Hepatocytes
2023cited by 0position: contributordoi
Data from A Pro-Regenerative Environment Triggers Premalignant to Malignant Transformation of Senescent Hepatocytes
2023cited by 0position: contributordoi
44d_RNAseq_data from A Pro-Regenerative Environment Triggers Premalignant to Malignant Transformation of Senescent Hepatocytes
2023cited by 0position: contributordoi
Primers from A Pro-Regenerative Environment Triggers Premalignant to Malignant Transformation of Senescent Hepatocytes
2023cited by 0position: contributordoi
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
Nature Medicine 2022cited by 612position: middledoi
Hypoxia‐driven immunosuppression by Treg and type‐2 conventional dendritic cells in HCC
Hepatology 2022cited by 156position: middledoi
Trajectory of immune evasion and cancer progression in hepatocellular carcinoma
Nature Communications 2022cited by 58position: middledoi
A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma.
2022cited by 15position: contributordoi
A Pro-Regenerative Environment Triggers Premalignant to Malignant Transformation of Senescent Hepatocytes
Cancer Research 2022cited by 12position: middledoi
IMbrave150: Exploratory efficacy and safety in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab beyond radiological progression until loss of clinical benefit in a global phase III study.
Journal of Clinical Oncology 2022cited by 11position: firstdoi
Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma
Nature Communications 2021cited by 137position: middledoi
Dynamic phenotypic heterogeneity and the evolution of multiple RNA subtypes in hepatocellular carcinoma: the PLANET study
National Science Review 2021cited by 84position: middledoi
Epstein–Barr Virus Epithelial Cancers—A Comprehensive Understanding to Drive Novel Therapies
Frontiers in Immunology 2021cited by 52position: lastdoi
Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma–Immune Humanized Mouse Model
Hepatology 2021cited by 49position: middledoi
Electroporation of NKG2D RNA CAR Improves Vγ9Vδ2 T Cell Responses against Human Solid Tumor Xenografts
Molecular Therapy — Oncolytics 2020cited by 61position: middledoi
Impact of the COVID-19 Epidemic on a Pan-Asian Academic Oncology Clinical Trial
JCO Global Oncology 2020cited by 13position: middledoi
Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis
Journal of Hepatology 2019cited by 141position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Yock Young Dan · National University of Singapore14 papers (2018–2025)Lars Zender · Deutsche Forschungsgemeinschaft13 papers (2022–2025) · 13 papers (2022–2025) · 13 papers (2022–2025) · 12 papers (2023–2025)Torsten Wüstefeld · Agency for Science, Technology and Research12 papers (2023–2025)Viktoriia Iakovleva · Agency for Science, Technology and Research12 papers (2023–2025)Anna Wuestefeld · 12 papers (2023–2025)Agnes Bee Leng Ong · Genome Institute of Singapore12 papers (2023–2025)Shirlyn Xue Ling Yap · 12 papers (2023–2025)Daniel Q. Huang · Second Affiliated Hospital of Xi'an Jiaotong University12 papers (2023–2025) · 12 papers (2023–2025)Pierce K. H. Chow · SingHealth10 papers (2012–2019)Alexander Yaw Fui Chung · SingHealth6 papers (2012–2019)Caroline Lee · Palo Alto University5 papers (2012–2019)London Lucien Ooi · National University of Singapore5 papers (2012–2019)Timothy Wai Ho Shuen · National Cancer Centre Singapore4 papers (2018–2024)Valerie Chew · Duke-NUS Medical School4 papers (2013–2018)Qingfeng Chen · National Chung Cheng University4 papers (2015–2024)Jerry Kok Yen Chan · National University of Singapore3 papers (2018–2024)